Strategies for Managing Your Uncontrolled Asthma Population

Science & Innovation Webinar

Webinar Recorded on Nov. 19, 2020 
Sponsored by GSK  

Asthma is a complex, heterogeneous clinical syndrome and remains a serious health risk in the US. According to the Centers for Disease Control, annual asthma-related rates include 3,441 deaths, 188,968 hospitalizations, and 1.8 million emergency department visits. Having uncontrolled asthma, significantly increases unscheduled doctor visits and hospitalizations, and is associated with higher healthcare costs.

Poor adherence to therapy plays a role in uncontrolled asthma. Barriers stem from a wide range of factors including environmental, patient, health system and therapeutic. Tools can help measure and manage adherence. However, ~30% of patients who are adherent to ICS/LABA remain uncontrolled. For these patients, factors to consider in your treatment protocols include:

• The goals of asthma management, which include symptom control and risk management
• Incorporating use of asthma control assessment tools and measures, including quality measures and how they are being used, and
• Recommendations from asthma guidelines on management, including non-pharmacologic and pharmacologic considerations

This program reviews the recommended tools for asthma assessment and management, as well as pharmacotherapy considerations to improve management and control. In addition, we review the GINA guidance for COVID-19 and asthma. These practical considerations will help managed care professionals better understand the complexity of uncontrolled asthma and ensure appropriate access using these evidence-based approaches.

Speaker:

• Riju Ray, MD, PhD
  Senior Medical Director, Respiratory
  US Medical Affairs, GSK

This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP. 

Sponsored by: